Pulmonary hypertension is associated with high morbidity and a poor prognosis. Medical therapies including PDE-5 inhibitors and ET-1 antagonists have led to symptomatic gains in carefully selected groups of patients, but the need for further developments remains apparent. Riociguat, the first in class of a new group which act as stimulators of soluble guanylate cyclase, […]